Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1158

1.

Differential role of cannabinoids in the pathogenesis of skin cancer.

Glodde N, Jakobs M, Bald T, Tüting T, Gaffal E.

Life Sci. 2015 Apr 25. pii: S0024-3205(15)00220-9. doi: 10.1016/j.lfs.2015.04.003. [Epub ahead of print]

PMID:
25921771
2.

The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

McAllister SD, Soroceanu L, Desprez PY.

J Neuroimmune Pharmacol. 2015 Apr 28. [Epub ahead of print]

PMID:
25916739
3.

A novel near-infrared fluorescence imaging probe that preferentially binds to cannabinoid receptors CB<sub>2</sub>R over CB<sub>1</sub>R.

Ling X, Zhang S, Shao P, Li W, Yang L, Ding Y, Xu C, Stella N, Bai M.

Biomaterials. 2015 Apr 24;57:169-178. doi: 10.1016/j.biomaterials.2015.04.018. [Epub ahead of print]

PMID:
25916505
4.

Cannabidiol stimulates Aml-1a-dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner.

Nabissi M, Morelli MB, Amantini C, Liberati S, Santoni M, Ricci-Vitiani L, Pallini R, Santoni G.

Int J Cancer. 2015 Apr 22. doi: 10.1002/ijc.29573. [Epub ahead of print]

PMID:
25903924
5.
6.

Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival.

Martínez-Martínez E, Gómez I, Martín P, Sánchez A, Román L, Tejerina E, Bonilla F, Merino AG, de Herreros AG, Provencio M, García JM.

Oncoscience. 2015 Feb 9;2(2):131-41. eCollection 2015.

7.

Role of Cannabinoid Receptor CB2 in HER2 Pro-oncogenic Signaling in Breast Cancer.

Pérez-Gómez E, Andradas C, Blasco-Benito S, Caffarel MM, García-Taboada E, Villa-Morales M, Moreno E, Hamann S, Martín-Villar E, Flores JM, Wenners A, Alkatout I, Klapper W, Röcken C, Bronsert P, Stickeler E, Staebler A, Bauer M, Arnold N, Soriano J, Pérez-Martínez M, Megías D, Moreno-Bueno G, Ortega-Gutiérrez S, Artola M, Vázquez-Villa H, Quintanilla M, Fernández-Piqueras J, Canela EI, McCormick PJ, Guzmán M, Sánchez C.

J Natl Cancer Inst. 2015 Apr 8;107(6). pii: djv077. doi: 10.1093/jnci/djv077. Print 2015 Jun.

PMID:
25855725
8.

Imaging the cannabinoid CB1 receptor in humans with [<sup>11</sup>C]OMAR: assessment of kinetic analysis methods, test-retest reproducibility, and gender differences.

Normandin MD, Zheng MQ, Lin KS, Mason NS, Lin SF, Ropchan J, Labaree D, Henry S, Williams WA, Carson RE, Neumeister A, Huang Y.

J Cereb Blood Flow Metab. 2015 Apr 1. doi: 10.1038/jcbfm.2015.46. [Epub ahead of print]

PMID:
25833345
9.

New approaches in the design and development of cannabinoid receptor ligands: multifunctional and bivalent compounds.

Nimczick M, Decker M.

ChemMedChem. 2015 May;10(5):773-86. doi: 10.1002/cmdc.201500041. Epub 2015 Mar 27.

PMID:
25820617
10.

Cannabinoids for the Treatment of Chronic Non-Cancer Pain: An Updated Systematic Review of Randomized Controlled Trials.

Lynch ME, Ware MA.

J Neuroimmune Pharmacol. 2015 Mar 22. [Epub ahead of print]

PMID:
25796592
11.

Genotoxic properties of representatives of alkylindazoles and aminoalkyl-indoles which are consumed as synthetic cannabinoids.

Koller VJ, Ferk F, Al-Serori H, Mišík M, Nersesyan A, Auwärter V, Grummt T, Knasmüller S.

Food Chem Toxicol. 2015 Mar 16;80:130-136. doi: 10.1016/j.fct.2015.03.004. [Epub ahead of print]

PMID:
25792264
12.

[268-POS]: Placental expression of the endocannabinoid system in preeclampsia.

Molvarec A, Fügedi G, Molnár M, Schönléber J, Kovalszky I, Rigó J Jr.

Pregnancy Hypertens. 2015 Jan;5(1):134. doi: 10.1016/j.preghy.2014.10.274. Epub 2015 Feb 23.

PMID:
25787618
13.

Cannabis in cancer care.

Abrams DI, Guzman M.

Clin Pharmacol Ther. 2015 Mar 16. doi: 10.1002/cpt.108. [Epub ahead of print]

PMID:
25777363
14.

Pharmacological options for the management of refractory cancer pain-what is the evidence?

Afsharimani B, Kindl K, Good P, Hardy J.

Support Care Cancer. 2015 May;23(5):1473-81. doi: 10.1007/s00520-015-2678-9. Epub 2015 Mar 7.

PMID:
25749509
15.

Δ9-Tetrahydrocannabinol-mediated epigenetic modifications elicit myeloid-derived suppressor cell activation via STAT3/S100A8.

Sido JM, Yang X, Nagarkatti PS, Nagarkatti M.

J Leukoc Biol. 2015 Apr;97(4):677-88. doi: 10.1189/jlb.1A1014-479R. Epub 2015 Feb 20.

PMID:
25713087
16.

Exploiting Cannabinoid-Induced Cytotoxic Autophagy to Drive Melanoma Cell Death.

Armstrong JL, Hill DS, McKee CS, Hernandez-Tiedra S, Lorente M, Lopez-Valero I, Eleni Anagnostou M, Babatunde F, Corazzari M, Redfern CP, Velasco G, Lovat PE.

J Invest Dermatol. 2015 Feb 10. doi: 10.1038/jid.2015.45. [Epub ahead of print]

PMID:
25674907
17.

Selective, nontoxic CB(2) cannabinoid o-quinone with in vivo activity against triple-negative breast cancer.

Morales P, Blasco-Benito S, Andradas C, Gómez-Cañas M, Flores JM, Goya P, Fernández-Ruiz J, Sánchez C, Jagerovic N.

J Med Chem. 2015 Mar 12;58(5):2256-64. doi: 10.1021/acs.jmedchem.5b00078. Epub 2015 Feb 20.

PMID:
25671648
18.
19.

Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti-tumor mechanisms of Cannabidiol in breast cancer.

Elbaz M, Nasser MW, Ravi J, Wani NA, Ahirwar DK, Zhao H, Oghumu S, Satoskar AR, Shilo K, Carson WE 3rd, Ganju RK.

Mol Oncol. 2015 Apr;9(4):906-19. doi: 10.1016/j.molonc.2014.12.010. Epub 2015 Jan 19.

PMID:
25660577
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk